Literature DB >> 31075159

Hepatitis C Virus RNA Levels Following Virologic Failure With Direct-acting Antivirals: Implications for Lower Sensitivity Diagnostic Assays.

Patrick R Harrington1, Takashi E Komatsu1, Hengrui Sun2, Lisa K Naeger1.   

Abstract

We analyzed post-treatment hepatitis C virus (HCV) RNA levels from 330 subjects who experienced virologic failure in clinical trials of direct-acting antivirals. We demonstrated that 97% had post-treatment Week 12 HCV RNA >10 000 IU/mL, above reported sensitivity limits of novel diagnostic assays being considered for simplified HCV treatment monitoring. Published by Oxford University Press for the Infectious Diseases Society of America 2019.

Entities:  

Keywords:  HCV RNA; HCV core antigen; direct-acting antivirals; hepatitis C virus; relapse

Year:  2020        PMID： 31075159     DOI： 10.1093/cid/ciz385

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  2 in total

1.  In-field evaluation of Xpert® HCV viral load Fingerstick assay in people who inject drugs in Tanzania.

Authors:  Zameer Mohamed; Jessie Mbwambo; John Rwegasha; Nicodem Mgina; Basra Doulla; Promise Mwakale; Edouard Tuaillon; Stephane Chevaliez; Yusuke Shimakawa; Simon D Taylor-Robinson; Mark R Thursz; Ashley S Brown; Maud Lemoine
Journal:  Liver Int       Date:  2019-12-15       Impact factor: 8.754

2.  Determining the lower limit of detection required for HCV viral load assay for test of cure following direct-acting antiviral-based treatment regimens: Evidence from a global data set.

Authors:  Jake R Morgan; Elizabeth Marsh; Alexandra Savinkina; Sonjelle Shilton; Shaun Shadaker; Tengiz Tsertsvadze; George Kamkamidze; Maia Alkhazashvili; Timothy Morgan; Pam Belperio; Lisa Backus; Waheed Doss; Gamal Esmat; Mohamed Hassany; Aisha Elsharkawy; Wafaa Elakel; Mai Mehrez; Graham R Foster; Constance Wose Kinge; Kara W Chew; Charles S Chasela; Ian M Sanne; Yin M Thanung; Anne Loarec; Khawar Aslam; Suna Balkan; Philippa J Easterbrook; Benjamin P Linas
Journal:  J Viral Hepat       Date:  2022-03-30       Impact factor: 3.517
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.